iShares Biotechnology ETF
649 hedge funds and large institutions have $4.6B invested in iShares Biotechnology ETF in 2018 Q4 according to their latest regulatory filings, with 112 funds opening new positions, 154 increasing their positions, 253 reducing their positions, and 83 closing their positions.
35% more first-time investments, than exits
New positions opened: 112 | Existing positions closed: 83
3% more funds holding
Funds holding: 631 → 649 (+18)
2.64% less ownership
Funds ownership: 64.63% → 61.99% (-2.6%)
18% less funds holding in top 10
Funds holding in top 10: 22 → 18 (-4)
27% less capital invested
Capital invested by funds: $6.3B → $4.6B (-$1.7B)
39% less repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 253
47% less call options, than puts
Call options by funds: $321M | Put options by funds: $610M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$64.7M |
| 2 |
Millennium Management
New York
|
+$45.2M |
| 3 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
+$44.8M |
| 4 |
LMIM
Lockheed Martin Investment Management
Bethesda,
Maryland
|
+$28.1M |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$152M |
| 2 |
Citigroup
New York
|
-$140M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$103M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$72.5M |
| 5 |
Goldman Sachs
New York
|
-$64M |
IBB Hedge Fund Activity: Q4 2018 in Review
649 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2018, worth a combined $4.6B — down 27% from $6.3B a quarter earlier.
Buyers outnumbered sellers: 112 funds opened new IBB positions and 83 closed out — a net gain of 29 holders — while 154 added to existing stakes and 253 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $64.7M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $152M.
- 649 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2018, up from 631 in Q3 2018.
- Funds reported $4.6B of iShares Biotechnology ETF stock for Q4 2018, down 27% quarter-over-quarter.
- 112 funds opened new iShares Biotechnology ETF positions in Q4 2018 and 83 closed out, a net change of +29 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2018 was JP Morgan Chase, an estimated $64.7M added.
- The largest iShares Biotechnology ETF seller in Q4 2018 was BNP Paribas Financial Markets, an estimated $152M sold.
Based on aggregated 13F filings for Q4 2018.